Seamless Therapeutics announces global research collaboration with Lilly to develop programmable recombinase-based therapeutics for hearing loss

Collaboration will advance a next generation gene editing approach by combining Seamless’ expertise in developing highly precise and efficient recombinases with Lilly’s extensive development expertise in genetic hearing disorders.

Companies will leverage Seamless’ recombinase technology to develop therapeutics for defined hearing loss indications.

Link to Seamless Therapeutics press release

Interview with Seamless Therapeutics CEO Dr. Albert Seymour (German article)